CO2023006808A2 - Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados - Google Patents

Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados

Info

Publication number
CO2023006808A2
CO2023006808A2 CONC2023/0006808A CO2023006808A CO2023006808A2 CO 2023006808 A2 CO2023006808 A2 CO 2023006808A2 CO 2023006808 A CO2023006808 A CO 2023006808A CO 2023006808 A2 CO2023006808 A2 CO 2023006808A2
Authority
CO
Colombia
Prior art keywords
treatment
hair loss
deuterated
regimens
loss disorders
Prior art date
Application number
CONC2023/0006808A
Other languages
English (en)
Spanish (es)
Inventor
James V Cassella
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of CO2023006808A2 publication Critical patent/CO2023006808A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2023/0006808A 2020-10-28 2023-05-25 Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados CO2023006808A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US202163155637P 2021-03-02 2021-03-02
PCT/US2021/057123 WO2022094133A1 (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
CO2023006808A2 true CO2023006808A2 (es) 2023-09-08

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006808A CO2023006808A2 (es) 2020-10-28 2023-05-25 Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados

Country Status (14)

Country Link
US (1) US20230390292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023553253A (cg-RX-API-DMAC7.html)
KR (1) KR20230093504A (cg-RX-API-DMAC7.html)
AU (1) AU2021372512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001201A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006808A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000085A (cg-RX-API-DMAC7.html)
IL (1) IL302401A (cg-RX-API-DMAC7.html)
JO (1) JOP20230090A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005027A (cg-RX-API-DMAC7.html)
PE (1) PE20231945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022094133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215520A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
MX2023005027A (es) 2023-07-31
AU2021372512A1 (en) 2023-06-22
JP2023553253A (ja) 2023-12-21
US20230390292A1 (en) 2023-12-07
PE20231945A1 (es) 2023-12-05
EP4236956A1 (en) 2023-09-06
CA3196551A1 (en) 2022-05-05
CL2023001201A1 (es) 2023-11-17
IL302401A (en) 2023-06-01
DOP2023000085A (es) 2023-07-31
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
JOP20230090A1 (ar) 2023-04-27
KR20230093504A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
CL2023001201A1 (es) Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados
MX2018013347A (es) Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2021001951A1 (es) Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los desordenes asociados a la edad.
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
CL2020000911A1 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
DOP2024000146A (es) Inhibidores de parp7
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
MX2025007935A (es) Nuevos inhibidores reversibles de dpp1 y usos de estos
CL2022001102A1 (es) Métodos para el tratamiento de trastornos depresivos.
PE20241326A1 (es) Composiciones y tratamientos con nirogacestat
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
DOP2025000009A (es) Inhibidores de acc novedosos
DOP2025000167A (es) Inhibidores de prmt5–mta
MX2024003258A (es) Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos.
MX2025006279A (es) Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a
MX2024013641A (es) Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak
AR133788A1 (es) Inhibidores de parp7
AR131842A1 (es) Métodos para tratar gliomas
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
AR128870A1 (es) Inhibidores de tyk2 y usos de los mismos
MX2023011686A (es) Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos.